Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Benzene ring containing

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514579000 - Nitrogen containing other than solely as a nitrogen in an inorganic ion of an addition salt, a nitro or a nitroso DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514649000 Amino nitrogen attached to aryl ring or aryl ring system by an acyclic carbon or acyclic chain 212
514656000 Polycyclo ring system 38
514648000 Two aryl rings or aryl ring systems bonded directly to the same acyclic carbon 32
514647000 Amino nitrogen and a ring bonded directly to the same ring and any other amino nitrogen in the compound is bonded directly to one of the rings 13
514658000 Two benzene rings bonded directly to the same nitrogen 2
20100113608Tryptase Enzyme Inhibiting Aminothiophenols - Disclosed herein are novel compounds and pharmaceutical compositions comprising these compounds. In some embodiments, the compounds are inhibitors of the tryptase enzyme and are useful for treating allergic rhinitis, asthma, vascular injury (e.g., restenosis and atherosclerosis), inflammatory bowel disease, arthritis, psoriasis, anaphylaxis, wounds, infections, and other allergy and inflammatory related diseases.05-06-2010
20120309844Substituted Diphenylamine Compounds, Preparation Method and Use Thereof - Substituted diphenylamine compounds of general formula I are provided, in which each substituted group is defined as in the description. The compounds of general formula I have broad-spectrum fungicidal activity in the field of agriculture. Furthermore, the preparation methods of the above compounds are simple.12-06-2012
Entries
DocumentTitleDate
20100113605METHODS, COMPOSITIONS AND USES THEREOF - The invention relates to a method for identifying a candidate compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission in the central nervous system, the method comprising the following steps: (a) providing a compound to be tested; (b) testing the ability of the compound to bind to the cocaine-binding site of a monoamine reuptake transporter; and (c) testing the ability of the compound to modulate the inward or outward transport of monoamine neurotransmitters via the monoamine reuptake transporter, wherein the test compound is identified as a candidate compound for treating a disorder or condition associated’ with dysfunction of monoamine neurotransmission if it is able to bind to the cocaine-binding site of the monoamine reuptake transporter and modulate its activity. The invention further relates to compounds identified using the method of the invention, and uses, compositions and medicaments thereof.05-06-2010
20100076085HCl Polymorphs of 3-((2-(Dimethylamino)methyl-(cyclohex-1-yl))phenol - A crystalline salt of 3-[2-(dimethylamino)methyl(cyclohex-1-yl)]phenol and hydrogen chloride, preferably in a 1:1 composition, including various crystalline forms of this salt, processes for preparing the various crystalline forms of this salt, pharmaceutical compositions containing the various crystalline forms of this salt, and the use of this salt as a pharmacologically active agent in a pharmaceutical composition to treat or inhibit pain or other disorders or disease states.03-25-2010
20130079417Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor - Highly selective 5-HT(2C) receptor agonists receptors are disclosed. The 5-HT(2C) receptor agonists are used in the treatments of disease and conditions wherein modulation of 5-HT(2C) receptors provides a benefit, such as obesity and psychiatric disorders.03-28-2013
20090156684LIQUID ANTIBACTERIAL COMPOSITIONS INCORPORATING TRICHLOROCARBANILIDE WITH REDUCED WATER ACTIVITY - A liquid antibacterial soap comprising trichlorocarbanilide, wherein the composition includes, 0.1-5 wt. % trichlorocarbanilide, 0-40 wt. % water, 0.1-40 wt. % of a surfactant or mixture of surfactants, 10-60 wt. % of lower glycols to render the composition visually clear and stable, and 0.1-10 wt. % of a mixture of additional adjuvant ingredients.06-18-2009
20130165526TOPICAL TREATMENT WITH DAPSONE IN G6PD-DEFICIENT PATIENTS - The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also provides methods of treating dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects.06-27-2013
20090012179Use of Tyrphostins to Stimulate Neurite Outgrowth - Disclosed herein are several methods for promoting nerve regeneration. The methods include administering at least one tyrphostin, or a pharmaceutically acceptable salt thereof. In one non-limiting example, the tyrphostin is tyrphostin A9. These methods can be used to promote nerve growth in the central or peripheral nervous system. The methods are of use in treating neurodegenerative diseases, such as Parkinson's disease, or in treating the transaction of a partial or complete transaction of a nerve in the peripheral or central nervous system.01-08-2009
20120035269CYCLOPROPENE AMINE COMPOUNDS - Methods of applying cyclopropene amine derivatives and compositions thereof to inhibit ethylene receptors in plants and plant material are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of at least one cyclopropene amine compound or composition thereof. Cyclopropene amine compounds, enantiomers, stereoisomers or salts thereof are also provided.02-09-2012
20100099774Method for Controlling Harmful Fungi - The present invention relates to a method for controlling phytopathogenic fungior harmful fungi in the protection of materials, wherein the fungi or the materials, plants, soil or seed to be protected against fungal attack are treated with a fungicidally effective amount of an amidrazone of the formula (I) wherein R, R04-22-2010
20090143478Milled Submicron Organic Biocides With Narrow Particle Size Distribution, and Uses Thereof - A method of milling substantially insoluble solid organic biocides to form a micron or sub-micron product having a narrow particle size distribution is presented. The milling involves wet milling of the organic biocide with high density milling media having a diameter between 0.1 mm and 0.8 mm, preferably between 0.2 mm and 0.7 mm, and a density equal to or greater than 3.8 g/cc, preferably greater than 5.5 g/cc, in a ball mill using between about 40% and 80% loading of the mill volume with milling media, and having the organic biocide suspended in an aqueous milling liquid which comprises one or more surface active agents. The milling speed is preferably high, for example from about 1000 rpm to about 4000 rpm. The milled product can be used in foliar applications at a lower effective dosage than prior art formulations, can be used in improved antifouling paint formulations, and can be used in new applications such as the direct injection of solid organic biocide particulates in wood to act as a long lasting wood preservative.06-04-2009
20100280126Method of Inhibiting Inflammatory Pain - A method of treating or inhibiting, in particular, pain caused by inflammation in a mammal by administering to the mammal an effective inflammatory pain alleviating amount of a (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol compound or a physiologically acceptable salt thereof, such as the hydrochloride or citrate salt.11-04-2010
20100099773INCLUSION COMPLEX OF SIBUTRAMINE AND BETA-CYCLODEXTRIN - The present invention relates to a sibutramine-containing inclusion complex having superior storage stability, and particularly to a pharmaceutically stable inclusion complex suitable for the drug formulation, which prepared by reacting a sibutramine (N,N-dimethyl-1-[1-(4-chlorophenyl)-cyclobutyl]-3-methylbutylamine) of Formula 1 and beta-cyclodextrin in a predetermined ratio, its preparation method and a pharmaceutical composition comprising the same.04-22-2010
20090163599Mif adsorbant - The present invention concerns an apheresis material or adsorbant and a method for removing, depleting or inactivating MIF (macrophage migration inhibitory factor) from blood, blood plasma, blood serum or other body fluids. The present invention is also concerned with the use of said apheresis material or adsorbant. In order to prepare a novel means and novel method, which can reduce the activity or amount of the mediator for sepsis and septic shock, MIF, in a patient's body fluid in a manner which is more pleasant and tolerable for the patient than prior art means and methods, the invention proposes that the apheresis material or adsorbant comprises a solid carrier material on the surface of which MIF-binding molecules or functional groups are immobilized. The method proposes that the apheresis material or adsorbant be brought into contact extracorporeally with the blood, blood plasma, blood serum or other body fluids.06-25-2009
20080319085TITRATION DOSING REGIMEN FOR CONTROLLED RELEASE TRAMADOL - A titration dosing regimen for the administration of controlled release tramadol analgesic to patients. The titration dosing regimen provides a significant reduction in the occurrence of adverse effects from the introduction of controlled released tramadol dosing, thus increasing patient compliance and medication tolerability.12-25-2008
20090326074Alkoxy compounds for disease treatment - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.12-31-2009
20090082466Abuse Resistant and Extended Release Formulations and Method of Use Thereof - The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioids, extended release pharmaceutical compositions of opioids and extended release abuse resistant pharmaceutical compositions of opioids and the use thereof for the treatment of pain. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of opioid abuse and/or opioid toxicity from either intentional or unintentional tampering.03-26-2009
20080262094Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction - The invention provides a method of treating comorbid premature ejaculation and erectile dysfunction. In particular, the method comprises administering an effective amount of a tramadol material and an effective amount of a phosphodiesterase inhibitor. The invention also provides a pharmaceutical composition comprising a pharmaceutically-acceptable carrier, a tramadol material and a phosphodiesterase inhibitor. The invention further provides a kit comprising a tramadol material and a phosphodiesterase inhibitor.10-23-2008
20080262095Protectant for UV-Induced Skin Damage - The present invention provides a method for protecting against UV radiation-induced skin damage. Specifically, compositions including dapsone are administered to provide UV protection. The dapsone compositions may be administered orally, or by other parenteral routes, such as topically, transdermally, by inhalation, and the like.10-23-2008
20110060053Crystalline Modifications of 6-Dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol - Crystalline modifications of (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol, (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol and mixtures thereof, pharmaceutical compositions and medicaments comprising these modifications, the use of these modifications as well as to a process for the enrichment of (1R,3R,6R)- or (1S,3S,6S)-6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol.03-10-2011
20100222434PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION - The present invention provides: a pharmaceutical composition for inhibiting amyloid-β protein accumulation comprising a compound of the formula (I) or a pharmaceutically acceptable salt thereof; a method for inhibiting amyloid-β protein accumulation, comprising a step of administering an effective amount of the compound of the formula (I) or a pharmaceutically acceptable salt thereof to a mammal which may be diagnosed with an amyloid-β protein-related disease; and so on.09-02-2010
20090197967COMPOSITIONS AND METHODS FOR TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS - Provided herein are compositions and methods for treating ophthalmic diseases and disorders. Compositions comprising retinylamine derivative compounds provided herein are useful for treating and preventing ophthalmic diseases and disorders, including diabetic retinopathy diabetic maculopathy, diabetic macular edema, retinal ischemia, ischemia-reperfusion related retinal injury, and metabolic optic neuropathy.08-06-2009
20090069439Use of pargyline for the treatment of hair folliclies - Use of Pargyline for the production of a medicament for influencing the metabolism of hair follicles and the modulation of their vital cycle.03-12-2009
20100069503INHIBITION OF MITOGEN-ACTIVATED PROTEIN KINASES IN CARDIOVASCULAR DISEASE - The present invention relates to methods for inhibiting subacute thrombosis and/or intimal hyperplasia following an interventional vascular procedure by contacting a blood vessel or a synthetic material with a mitogen-activated protein kinase (MAPK) pathway inhibitor. The present invention further relates to vascular devices comprising a MAPK pathway inhibitor.03-18-2010
20110251286Crystalline salts and/or co-crystals of O-desmethyltramadol - Salts and/or co-crystals of (+)-3-[2-(dimethylamino)-methyl-1-hydroxycyclohexyl]-phenol or of (−)-3-[2-(dimethylamino)methyl-1-hydroxy-cyclohexyl]phenol, present in crystalline form, with cinnamic acid, C10-13-2011
20110152379COMPOSITION FOR CONTROL OF AGING AND/OR EXTENSION OF LIFE, CONTAINING DAPSONE AS ACTIVE INGREDIENT - The present invention relates to a composition for controlling aging and/or extending lifespan. More specifically, the present invention relates to a composition containing dapsone as an effective component for controlling aging and/or extending lifespan, in which when applying the composition according to the present invention to an object, the effect of controlling aging or extending lifespan is excellent. Specifically, the treatment of dapsone (DDS) increases the lifespan of 06-23-2011
20100063159Use of dapsone as a neuroprotector in cerebral infarction - The use of dapsone is the first effective treatment against the disabling consequences associated with cerebral infarction in patients. Dapsone was evaluated as a neuroprotector in the cerebral infarction model produced by the occlusion of the middle cerebral artery in rats and in patients suffering from acute cerebral infarction caused by thromboembolism. In both studies, dapsone displayed a reduction of between 70 and 90% in the adverse effects which occur as a consequence of the infarction.03-11-2010
20080214677Chitosan-Silicon Dioxide Coprecipitate and Use as Excipient in Solid Dosage Forms - Chitosan silicon dioxide coprecipitate composition, method of production thereof, pharmaceutical composition comprising the chitosan silicon dioxide coprecipitate composition and use of the chitosan silicon dioxide coprecipitate composition for manufacturing a sustained or immediate release formulation.09-04-2008
20080214676DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS - The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.09-04-2008
20100190861CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS - The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.07-29-2010
20100210732Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor - The present invention is directed to pharmaceutical compositions and the use thereof for preventing or minimizing the intensity of the serotonin syndrome. The present invention is directed at a method of preventing or minimizing the intensity of the serotonin syndrome in humans which comprises administering proserotonergic agents and serotonin surge protectors, wherein said concurrent administration reduces or prevents serotonin excess, which is the cause of the serotonin syndrome. The present invention is also directed to pharmaceutical compositions comprising proserotonergic agents and serotonin surge protectors useful for carrying out the method of the present invention.08-19-2010
20110306673CRYSTALLINE FORMS OF (1RS,2RS,6RS)-6-DIMETHYLAMINOMETHYL-1-(3-METHOXYPHENYL)CYCLOHEXANE-1,3-DI- OL HYDROCHLORIDE - This invention relates to solid crystalline forms of (1RS,3RS,6RS)-6-Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutical compositions comprising 1.12-15-2011
20090137684SUSTAINED-RELEASE PREPARATIONS AND METHOD FOR PRODUCING THE SAME - The present invention relates to sustained-release preparations prepared by double granulation and methods for producing the same. The sustained-release preparations according to the present invention enables maintenance of effective blood concentration of drug for many hours via sustained release of the drug over 12 hours or more, and further its production is easy owing to convenience of process.05-28-2009
20100029781METHODS FOR PREPARATION OF ANTI-ACNE FORMULATION AND COMPOSITIONS PREPARED THEREBY - The present invention provides methods to make solvent-microparticle (SMP) topical formulations for bioactive drugs. The formulations, which are aqueous gels containing undissolved solid drug, include a drug in a solution which can permeate the stratum corneum layer of the epidermis and the drug in an undissolved microparticulate solid form that does not readily cross the stratum corneum. The solid form is retained in or above the stratum corneum to serve as a reservoir or to provide drug action in the supracorneum zone. The fine, particulate solid component of the invention can confer a smooth, nongritty feel against the skin.02-04-2010
20120059065Tamper Resistant Dosage Form Comprising An Anionic Polymer - A pharmaceutical dosage form and method of using same, the pharmaceutical dosage form exhibiting a breaking strength of at least 500 N, said dosage form containing 03-08-2012
20120157541SOLUBLE PHARMACEUTICAL FORMULATIONS OF N,N-DIAMINODIPHENYL SULFONE FOR OPTIMAL USE IN THE TREATMENT OF VARIOUS DISEASES - The present invention aims to demonstrate that a soluble pharmaceutical formulation can be prepared of N,N′-Diamino-diphenyl sulfone which is useful in the development of an ideal drug for use against cerebral infarction, epilepsy, traumatic spinal cord injury, cranio-encephalic trauma, leprosy, 06-21-2012
20110092602RAPIDLY DISINTEGRATING ORAL COMPOSITIONS OF TRAMADOL - The present invention relates to a stable taste masked orally disintegrating pharmaceutical composition of tramadol comprising of 3% to 30% w/w of tramadol, 2% to 30% w/w of an ion exchange resin, 0.01 to about 2% w/w of binder and pharmaceutically acceptable excipients to equal 100% w/w, wherein the binder used is gelatin.04-21-2011
20090076159DEUTERIUM-ENRICHED EPLIVANSERIN - The present application describes deuterium-enriched eplivanserin, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20120225949COMPOSITIONS AND METHODS FOR TREATING BIPOLAR DISORDER - The present invention is directed to a method for treating symptoms associated with bipolar disorder. The method includes administering to a subject in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with bipolar disorder, childhood-onset bipolar disorder, or childhood-onset bipolar disorder with Fear of Harm.09-06-2012
20090149548NOVEL 1,2-DIPHENYLETHENE DERIVATIVES FOR TREATMENT OF IMMUNE DISEASES - The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases.06-11-2009
20110269840TREATING RENAL CANCER USING A 4-[BIS[2-[(METHYLSULFONYL)OXY]ETHYL]AMINO]-2-METHYL-BENZALDEHYDE - The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment methods provided herein.11-03-2011
20130018104EMULSIVE COMPOSITION CONTAINING DAPSONE - The present invention relates to a topical, emulsive composition containing Dapsone or its derivative. The inventive composition incorporates emollients and Dapsone or its derivative in a stable emulsion. The stability is achieved through the use of a combination of certain surfactant mixtures and an enhancer providing solubility of the Dapsone.01-17-2013
20130178536SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS - The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.07-11-2013
20110294896Topical Treatment With Dapsone In G6PD-Deficient Patients - The present invention provides a pharmaceutical carrier system comprising a dermatological composition that is a semi-solid aqueous gel, wherein dapsone is dissolved in the gel such that the dapsone has the capacity to cross the stratum corneum layer of the epidermis, and wherein the composition also contains dapsone in a microparticulate state that does not readily cross the stratum corneum of the epidermis. The present invention also discloses the treatment of dermatological conditions in G6PD-deficient patients with the composition, while avoiding adverse hematologic effects.12-01-2011

Patent applications in class Benzene ring containing

Patent applications in all subclasses Benzene ring containing